Research programme: hepatitis B virus therapy - Novita Healthcare
Alternative Names: AM-491; AVX-491Latest Information Update: 24 Mar 2017
At a glance
- Originator Avexa
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 31 May 2004 Avexa Ltd., has been established as a spin-out of AMRAD's anti-infectives drug portfolio
- 22 Jan 2003 This programme is still in active development
- 25 Sep 2000 Preclinical development for Hepatitis B in Australia (Unknown route)